Clinverse

The company's flagship product was the ClinPay Financial Lifecycle System, a software-as-a-service (SaaS) platform. This system was designed to integrate with existing clinical trial management systems (CTMS) to streamline the payment process. Its core function was to automate payments to investigator sites and other service providers, which helped to reduce administrative workload, improve accuracy, and lower operational costs for its clients. The platform could handle transactions in over 140 currencies across more than 200 countries, accommodating the global nature of clinical research. Clinverse also offered ClinDebit, which facilitated payments to trial subjects through real-time loaded debit cards. The business model centered on providing these technology solutions to pharmaceutical companies and contract research organizations (CROs).

Throughout its history, Clinverse secured significant funding, raising a total of $15.6 million over four rounds to support its growth and market penetration. Notable investors included Edison Partners, Hatteras Venture Partners, and Vital Venture Capital. The company was led by CEO Jay Trepanier, and Denis Connaghan also served as CEO, bringing extensive experience from the healthcare and technology sectors. In January 2016, Clinverse was acquired by Bioclinica, a larger provider of clinical trial services and technology. The acquisition was a strategic move for Clinverse, allowing it to leverage Bioclinica's established customer base and financial stability to pursue larger opportunities. Following the acquisition, Clinverse became part of Bioclinica's eHealth Solutions business segment.